Physicochemical Properties
| Molecular Formula | C24H24N6O |
| Molecular Weight | 412.49 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | PLK4 5.2 nM (Kd) PLK2 653 nM (Kd) PLK1 >10000 nM (Kd) PLK3 >10000 nM (Kd) |
| ln Vitro | In a dose-dependent manner, YLT-11 (0-1 µM; 48 h) lowers the expression of p-PLK4 [1]. Cell cycle arrest and apoptosis are induced in the G2/M phase by YLT-11 (0-0.5 µM; 0-48 h) [1]. |
| ln Vivo | YLT-11 (30, 90 mg/kg; oral; once daily for 20 days) demonstrates in mice anticancer activities [1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: MDA-MB-231, MDA-MB-468, BT549, MCF-7 cells Tested Concentrations: 0-10 µM Incubation Duration: 24-96 h Experimental Results: demonstrated antiproliferative activity in a time-dependent and concentration-dependent manner with IC50s of 120, 68, 73, 74 nM for MDA-MB-231, MDA-MB-468, BT549, MCF-7 cells, respectively. Western Blot Analysis[1] Cell Types: MDA-MB -468, MDA-MB-231 cells Tested Concentrations: 0, 0.25, 0.5, 1 µM Incubation Duration: 48 h Experimental Results: diminished the expression of p-PLK4 in a dose-dependent manner. Cell Cycle Analysis[1] Cell Types: MDA -MB-468, MDA-MB-231 cells Tested Concentrations: 0.25 µM Incubation Duration: 0-48 h Experimental Results: Induced cell cycle arrest at G2/M phase. Apoptosis Analysis[1] Cell Types: MDA-MB-468, MDA- MB-231 cells Tested Concentrations: 0, 0.125, 0.25, 0.5 µM Incubation Duration: 24, 48 h Experimental Results: Induced apoptosis of cancer cells in a time-dependent and concentration-dependent manner with the expression of cleaved caspase-3 and cleaved PARP1 increased . |
| Animal Protocol |
Animal/Disease Models: Sixweeks old female BALB/c nude mice[1] Doses: 30, 90 mg/kg Route of Administration: Po; daily for 20 days Experimental Results: Remarkably inhibited the growth of tumor xenografts in a dose-dependent manner. |
| References |
[1]. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis. 2018 Oct 18;9(11):1066. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4243 mL | 12.1215 mL | 24.2430 mL | |
| 5 mM | 0.4849 mL | 2.4243 mL | 4.8486 mL | |
| 10 mM | 0.2424 mL | 1.2122 mL | 2.4243 mL |